ArticleAnnals of hematology2025

Enasidenib as treatment for AML with IDH2 mutation: multicenter real-life study of the early-access program in Spain.

Carlos Jiménez-Vicente et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.